Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.
Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.
复制标题
八聚体结合转录因子 4 对实体瘤患者的预后价值：荟萃分析
DOI：
10.1097/md.0000000000022804
复制
发表时间：
2020-10-16
期刊：
影响因子：
1.6
通讯作者：
Wang H
中科院分区：
文献类型：
--
作者：
Zhao X;Lu H;Sun Y;Liu L;Wang H
八聚体结合转录因子4(Oct4)在肿瘤的发生发展过程中起着至关重要的作用，被认为是预测肿瘤预后的潜在生物标志物。然而，OCT4在实体瘤患者中的预后价值仍然难以捉摸。在此，我们进行了一项荟萃分析，以评估Oct4在实体瘤患者中的预后价值。我们在PubMed、Embase和Web of Science数据库上进行了文献搜索，以检索截至2019年12月发表的全面且符合条件的研究。这项研究是根据系统回顾和荟萃分析指南的首选报告项目进行的。用总生存期(OS)和无病生存期(DFS)/无复发生存期(RFS)/无进展生存期(PFS)的95%可信区间的合并风险比(HRs)通过随机模型和固定效应模型评价Oct4对实体瘤患者的预后价值。总共有36项研究、5198名患者被纳入荟萃分析。值得注意的是，Oct4表达升高与OS(合并HR：2.02，95%CI：1.55-2.62，P <； .001)和DFS/RFS/PFS(合并HR：2.34，95%CI：1.88-2.92，P <； .001)相关。本研究表明，Oct4在肝细胞癌(OS，DFS/RFS/PFS)、食道鳞状细胞癌(OS)、胃癌(OS)、宫颈癌(OS，DFS/RFS/PFS)和结直肠癌(OS，DFS/RFS/PFS)等实体瘤患者中呈高表达，提示Oct4可作为预测肿瘤预后的潜在生物标志物。
Octamer binding transcription factor 4 (Oct4) is critically important in the development and progression of cancer, and is considered a potential biomarker for tumor prognosis. However, the prognostic value of Oct4 in patients with solid tumors remains elusive. Herein, we conducted a meta-analysis to assess the prognostic value of Oct4 in patients with solid tumors. We conducted a literature search on PubMed, Embase, and Web of Science databases to retrieve comprehensive and eligible studies published until December 2019. The study was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS)/progress-free survival (PFS) were used to evaluate the prognostic value of Oct4 in patients with solid tumors via either random or fixed-effects models. In total, 36 studies with 5198 patients were included in the meta-analysis. Notably, elevated Oct4 expression was associated with worse OS (pooled HR: 2.02, 95% CI: 1.55–2.62, P < .001) and DFS/RFS/PFS (pooled HR: 2.34, 95% CI: 1.88–2.92, P < .001). This work demonstrated that patients with solid tumors show high expression of Oct4 which is linked to worse prognosis in patients with solid tumors including hepatocellular carcinoma (OS, DFS/RFS/PFS), esophageal squamous cell carcinoma (OS), gastric cancer (OS), cervical cancer (OS, DFS/RFS/PFS), and colorectal cancer (OS, DFS/RFS/PFS), this implicated Oct4 as a potential biomarker to predict the prognosis of tumors.
DOI：
10.3779/j.issn.1009-3419.2013.04.05
发表时间：
2013-04
期刊：
Zhongguo fei ai za zhi = Chinese journal of lung cancer
影响因子：
--
作者：
Zhang X;Wang H;Jin B;Dong Q;Huang J;Han B
通讯作者：
Han B